Literature DB >> 31826649

Atrial Fibrillation-Mediated Cardiomyopathy.

Dingxin Qin1, Moussa C Mansour1, Jeremy N Ruskin1, Edwin Kevin Heist1.   

Abstract

AF-mediated cardiomyopathy (AMC) is an important reversible cause of heart failure that is likely underdiagnosed in today's clinical practice. AMC describes AF either as the sole cause for ventricular dysfunction or exacerbating ventricular dysfunction in patients with existing cardiomyopathy or heart failure. Studies suggest that irreversible ventricular and atrial remodeling can occur in AMC, making timely diagnosis and intervention critical to optimize clinical outcome. Clinical correlation between AF onset/burden and progression of cardiomyopathy/heart failure symptoms provides strong evidence for the diagnosis of AMC. Cardiac MRI, continuous cardiac monitoring, and biomarkers are important diagnostic tools. From the therapeutic standpoint, early data suggest that AF ablation may improve long-term outcomes in AMC patients compared with medical rate and rhythm control. Patients with more AF burden and less severe underlying structural heart disease are more likely to experience left ventricle function recovery with successful AF ablation. Despite recent advances, significant knowledge gaps exist in our understanding of the epidemiology, mechanisms, diagnosis, management strategies, and prognosis of AMC.

Entities:  

Keywords:  atrial fibrillation; atrial remodeling; biomarkers; cardiomyopathies; heart failure

Year:  2019        PMID: 31826649     DOI: 10.1161/CIRCEP.119.007809

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  5 in total

Review 1.  Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights.

Authors:  Jelena Kornej; Christin S Börschel; Emelia J Benjamin; Renate B Schnabel
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

2.  Identification of Functional Genetic Determinants of Cardiac Troponin T and I in a Multiethnic Population and Causal Associations With Atrial Fibrillation.

Authors:  Yunju Yang; Traci M Bartz; Michael R Brown; Xiuqing Guo; Nuno R Zilhão; Stella Trompet; Stefan Weiss; Jie Yao; Jennifer A Brody; Christopher R Defilippi; Ron C Hoogeveen; Henry J Lin; Vilmundur Gudnason; Christie M Ballantyne; Marcus Dörr; J Wouter Jukema; Astrid Petersmann; Bruce M Psaty; Jerome I Rotter; Eric Boerwinkle; Myriam Fornage; Goo Jun; Bing Yu
Journal:  Circ Genom Precis Med       Date:  2021-11-04

3.  ExPheWas: a platform for cis-Mendelian randomization and gene-based association scans.

Authors:  Marc-André Legault; Louis-Philippe Lemieux Perreault; Jean-Claude Tardif; Marie-Pierre Dubé
Journal:  Nucleic Acids Res       Date:  2022-04-26       Impact factor: 19.160

4.  Mortality risk and temporal patterns of atrial fibrillation in the nationwide registry.

Authors:  Sirin Apiyasawat; Sakaorat Kornbongkotmas; Ply Chichareon; Rungroj Krittayaphong
Journal:  J Arrhythm       Date:  2021-10-06

5.  Suppression of amiodarone-induced torsade de pointes by landiolol in a patient with atrial fibrillation-mediated cardiomyopathy.

Authors:  Koji Takahashi; Mina Yamashita; Tomoki Sakaue; Daijiro Enomoto; Shigeki Uemura; Takafumi Okura; Shuntaro Ikeda; Masafumi Takemoto; Yutaka Utsunomiya; Takashi Hyodo
Journal:  Ann Noninvasive Electrocardiol       Date:  2021-03-23       Impact factor: 1.468

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.